Companion Pharmacogenetic Study to UMCC 9900/9901

Stopped early

Conditions studied: Metastatic Breast Cancer

In brief

The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.

Key facts

Study ID

NCT00146029

Run by

University of Michigan Rogel Cancer Center

Last updated by the study team

2008-03-26

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients who participated on UMCC 9900/9901
• Living patients must give written informed consent

You may not qualify if…

• No tumor block tissue available

Where it is running

• University of Michigan Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.